Wall Street investors reacted favorably to Teva Pharmaceutical Industries’ decision to abandon its hostile takeover attempt for Mylan NV in favor of buying Allergan’s generic drug business for $40.5 billion. In late afternoon trading, Teva’s stock ...
Mylan Chief Heather Bresch's comments on CNBC's "Power Lunch" came two days after the firm's stock price spiked sharply when the company reported adjusted earnings per share of $1.57, which beat a Thomson Reuters consensus …
MSN2mon
Heather Bresch
Analysts await Mylan N.V. (NASDAQ:MYL) to report earnings on May, 10 before the open. The firm now has a "buy" rating on the stock. A number of equities analysts recently issued reports on the company. The stock's 50 day moving …
New Mexico
With parents expressing their outrage over the EpiPen price hikes and lawmakers saying they will be investigating the …
Alternatives
However, she noted, “It's still a huge profit margin for them." Mylan’s stock took a 10 percent hit last week after a number of senators called on the drug maker to explain the runaway cost of the life-saving injector. Senator Amy Klobuchar (D ...
RT9mon
300
05/12 Fresh off an M&A spree, Mylan may need another buy to keep growing: a.. 05/12 Mylan $MYL Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPS .. 05/12 Fresh off an M&A spree, Mylan may need another buy …
Mylan N.V. (NASDAQ:MYL) announced its financial results for the quarter ended March 31, 2017. Haniya told a news conference held in Gaza city that the suspect, who murdered Mazen Fuqaha, confessed to the crime. More details will …
Mylan Inc. (NASDAQ: MYL) is one of the world's biggest drugmakers, and it's also one of Fool contributor Todd Campbell's worst-performing stock picks. The company's EpiPen fiasco, and worries over investigations into generic-drug pricing, …
Mylan N.V. (MYL) down -5.71 per cent in the past week, is under coverage of 20 analysts who collectively recommend a hold rating on stock. 12 of the analysts have a buy or better rating; the 8 sells versus 0 holds. The 16 equity analysts …
NEW YORK (CNNMoney.com) -- Mylan Pharmaceuticals' stock plunged after the drugmaker said it was purchasing the generic arm of German drug giant Merck KGaA. Mylan (down $2.49 to $19.91, Charts) stock fell more than 13 percent …